Stryker Corporation $SYK Stock: Sumitomo Mitsui Trust Group Inc. Increases Stake

Key Points

• Institutional ownership increased: Sumitomo Mitsui Trust Group raised its Stryker stake by 3.5% to 767,516 shares, while institutional investors collectively own 77.09% of the company.
• Quarterly results missed estimates: Stryker reported $6.52 billion in revenue and $3.52 in EPS, below consensus expectations, although revenue grew 7.6% year over year. The company lowered its 2026 outlook amid weaker joint-replacement demand and operational disruptions.
• Analysts remain cautiously positive: Stryker has a “Moderate Buy” consensus rating from analysts, with a $355.84 average price target, despite several recent target reductions and some hold ratings.

Sumitomo Mitsui Trust Group Inc. grew its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 3.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 767,516 shares of the medical technology company's stock after acquiring an additional 26,311 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.20% of Stryker worth $211,366,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Stryker during the third quarter valued at approximately $25,964,000. ProShare Advisors LLC lifted its position in Stryker by 15.0% in the 3rd quarter. ProShare Advisors LLC now owns 63,119 shares of the medical technology company's stock valued at $17,382,000 after acquiring an additional 8,243 shares in the last quarter. Grandfield & Dodd LLC boosted its position in Stryker by 0.8% during the 3rd quarter. Grandfield & Dodd LLC now owns 98,086 shares of the medical technology company's stock worth $27,012,000 after acquiring an additional 775 shares during the last quarter. Cidel Asset Management Inc. grew its holdings in shares of Stryker by 5.9% in the 3rd quarter. Cidel Asset Management Inc. now owns 2,203 shares of the medical technology company's stock valued at $607,000 after acquiring an additional 123 shares in the last quarter. Finally, Intrua Financial LLC increased its position in shares of Stryker by 2.3% during the 3rd quarter. Intrua Financial LLC now owns 1,939 shares of the medical technology company's stock worth $534,000 after purchasing an additional 43 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. BTIG Research dropped their price objective on Stryker from $316.00 to $304.00 and set a "buy" rating on the stock in a research note on Friday. Piper Sandler dropped their price objective on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. TD Cowen cut their target price on shares of Stryker from $298.00 to $290.00 and set a "hold" rating for the company in a research note on Friday. BMO Capital Markets restated an "outperform" rating and issued a $309.00 price target on shares of Stryker in a research note on Friday. Finally, Barclays dropped their price target on Stryker from $375.00 to $365.00 and set an "overweight" rating for the company in a research note on Friday. Sixteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, Stryker has a consensus rating of "Moderate Buy" and a consensus price target of $355.84.

Stryker Trading Down 0.1%

NYSE:SYK opened at $291.56 on Monday. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The firm has a fifty day simple moving average of $292.83 and a two-hundred day simple moving average of $324.51. The stock has a market capitalization of $111.83 billion, a price-to-earnings ratio of 31.05, a PEG ratio of 1.89 and a beta of 0.78.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. During the same quarter last year, the business posted $3.19 earnings per share. Stryker's revenue was up 7.6% on a year-over-year basis. Analysts expect that Stryker Corporation will post 14.85 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date was Wednesday, September 30th. Stryker's dividend payout ratio is currently 37.49%.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. Insiders own 4.60% of the company's stock.

Stryker Profile

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.